Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

NCT01962792 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Ibrutinib
DRUG: Carfilzomib
DRUG: Dexamethasone

Sponsor

Pharmacyclics LLC.